Abstract：
BACKGROUND: Alzheimer\'s disease (AD) is a widespread neurological illness in the elderly, which impacted about 50 million people globally in 2020. Type 2 diabetes has been identified as a risk factor. Insulin and incretins are substances that have various impacts on neurodegenerative processes. Preclinical research has shown that GLP-1 receptor agonists decrease neuroinflammation, tau phosphorylation, amyloid deposition, synaptic function, and memory formation. Phase 2 and 3 studies are now occurring in Alzheimer\'s disease populations. In this article, we present a detailed assessment of the therapeutic potential of GLP-1 analogues and DPP4 inhibitors in Alzheimer\'s disease.
OBJECTIVE: This study aimed to gain insight into how GLP-1 analogues and associated antagonists of DPP4 safeguard against AD.
METHODS: This study uses terms from search engines, such as Scopus, PubMed, and Google Scholar, to explore the role, function, and treatment options of the GLP-1 analogue for AD.
RESULTS: The review suggested that GLP-1 analogues may be useful for treating AD because they have been linked to anti-inflammatory, neurotrophic, and neuroprotective characteristics. Throughout this review, we discuss the underlying causes of AD and how GLP signaling functions.
CONCLUSIONS: With a focus on AD, the molecular and pharmacological effects of a few GLP-1/GIP analogs, both synthetic and natural, as well as DPP4 inhibitors, have been mentioned, which are in the preclinical and clinical studies. This has been demonstrated to improve cognitive function in Alzheimer\'s patients.
OBJECTIVE: This study aimed to gain insight into how GLP-1 analogues and associated antagonists of DPP4 safeguard against AD.
METHODS: This study uses terms from search engines, such as Scopus, PubMed, and Google Scholar, to explore the role, function, and treatment options of the GLP-1 analogue for AD.
RESULTS: The review suggested that GLP-1 analogues may be useful for treating AD because they have been linked to anti-inflammatory, neurotrophic, and neuroprotective characteristics. Throughout this review, we discuss the underlying causes of AD and how GLP signaling functions.
CONCLUSIONS: With a focus on AD, the molecular and pharmacological effects of a few GLP-1/GIP analogs, both synthetic and natural, as well as DPP4 inhibitors, have been mentioned, which are in the preclinical and clinical studies. This has been demonstrated to improve cognitive function in Alzheimer\'s patients.
摘要：
背景：阿尔茨海默病（AD）是老年人普遍存在的神经系统疾病，这在2020年影响了全球约5000万人。2型糖尿病已被确定为危险因素。胰岛素和肠促胰岛素是对神经退行性过程有各种影响的物质。临床前研究表明，GLP-1受体激动剂减少神经炎症，tau磷酸化，淀粉样蛋白沉积,突触功能，和记忆形成。2期和3期研究目前正在阿尔茨海默病人群中进行。在这篇文章中,我们详细评估了GLP-1类似物和DPP4抑制剂对阿尔茨海默病的治疗潜力.
目的：本研究旨在深入了解GLP-1类似物和DPP4相关拮抗剂如何预防AD。
方法：本研究使用来自搜索引擎的术语，比如Scopus,PubMed,和谷歌学者，探索角色，函数,和GLP-1类似物对AD的治疗选择。
结果：该综述表明GLP-1类似物可能对治疗AD有用，因为它们与抗炎有关。神经营养，和神经保护特性。在整个审查过程中，我们讨论了AD的根本原因以及GLP信号如何发挥作用。
结论：以AD为重点，一些GLP-1/GIP类似物的分子和药理作用，合成和天然，以及DPP4抑制剂，已经被提到，在临床前和临床研究中。这已被证明可以改善阿尔茨海默病患者的认知功能。
目的：本研究旨在深入了解GLP-1类似物和DPP4相关拮抗剂如何预防AD。
方法：本研究使用来自搜索引擎的术语，比如Scopus,PubMed,和谷歌学者，探索角色，函数,和GLP-1类似物对AD的治疗选择。
结果：该综述表明GLP-1类似物可能对治疗AD有用，因为它们与抗炎有关。神经营养，和神经保护特性。在整个审查过程中，我们讨论了AD的根本原因以及GLP信号如何发挥作用。
结论：以AD为重点，一些GLP-1/GIP类似物的分子和药理作用，合成和天然，以及DPP4抑制剂，已经被提到，在临床前和临床研究中。这已被证明可以改善阿尔茨海默病患者的认知功能。
